Month: August 2022

Navitas Semiconductor Navitas SemiconductorRevenues Increased 58% with important market and regional diversification, while guidance reflects short-term China smartphone softness 20+ significant new wins in mobile chargers, plus accelerating progress in customer development in the solar, EV, data center and industrial markets GeneSiC acquisition positions Navitas as the only pure-play, next-generation power semiconductor company with broad diversification, synergistic customers and 2-3 year acceleration into strategic EV, solar and energy storage marketsEL SEGUNDO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) — Navitas Semiconductor Corporation (Nasdaq: NVTS), the industry leader in next-generation power semiconductors, today announced unaudited financial results for the second quarter ended June 30, 2022. Net revenues for the...

DALLAS, Aug. 15, 2022 (GLOBE NEWSWIRE) — Hallmark Financial Services, Inc. (“Hallmark”) (NASDAQ: HALL) today announced financial results for the second quarter and six months ended June 30, 2022.  Second Quarter   Year-to-Date    2022 2021   2022 2021  $ in millions:            Net (Loss) Income $ (69.4 ) $ (0.8 )   $ (72.6 ) $ 8.1  Operating (Loss) Income (1) $ (42.4 ) $ (3.9 )   $ (45.6 ) $ 0.5               $ per diluted share:            Net (Loss) Income $ (3.82 ) $ (0.05 )   $ (4.00 ) $ 0.45  Operating (Loss) Income (1) $ (2.33 ) $ (0.22 )   $ (2.51 ) $ 0.03  (1)   See “Non-GAAP Financial Measures” below Highlights:Net loss of $69.4 million, or $3.82 per share, in the second quarter of 2022 as compared to a net loss of $0.8 million, or $0.05 per share, for the same period of 2021. Year-to-date...

FORT WORTH, Texas, Aug. 15, 2022 (GLOBE NEWSWIRE) — Tandy Leather Factory, Inc. (Pink: TLFA) today announced the Company’s financial results for the second quarter ended June 30, 2022. Second Quarter Highlights:Net sales of $18.4 million Gross profit of $10.5 million and a gross margin of 57.0% Operating loss of $0.7 million Net loss of $0.6 million, or $0.07 per diluted share Adjusted EBITDA* of ($0.1 million) Ended the quarter with $5.6 million in cash and cash equivalentsJanet Carr, Chief Executive Officer of the Company, said, “Our second quarter net sales were down less than 1%, better than the trend we saw during the first quarter, largely as a result of adjustments we made in response to the continued lower consumer demand driven by inflation and uncertainty related to ongoing global political, economic and public health...

Second quarter 2022 revenue of $14.1 million, bringing year to date revenue to $37.1 million. Reducing 2022 revenue guidance to $80-90 million to account for ongoing variability in core service business, macroeconomic and commercial factors. Maintaining substantial cash, cash equivalents, and current investments of $619.1 million at quarter end; Reducing operating expenses by $75 million through 2023-end to navigate market. Ongoing strategic plans including announced acquisition of Palamedrix for next-generation SomaScan reader; Illumina protein sequencer on track for 2024 launch; accelerating broad-based initiatives to grow scale and commercial team.BOULDER, Colo., Aug. 15, 2022 (GLOBE NEWSWIRE) —  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended June 30,...

Quarterly revenue of $76.4 million, representing 27% growth year-over-year. Second quarter gross margin of 68.9% and gross profit growth of 19% year-over-year. Record gross margins in our US business of 74.2%. Active Buyers of 1.7 million and Orders of 1.7 million in Q2 2022, representing growth of 29% and 40% year-over-year, respectively. Published the 10th Annual Resale Report in May, revealing that the U.S. secondhand market is projected to more than double by 2026, reaching $82 billion.OAKLAND, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) — ThredUp Inc. (Nasdaq: TDUP), one of the largest online resale platforms for women’s and kids’ apparel, shoes, and accessories, announced today its financial results for the second quarter ended June 30, 2022. “Demonstrating the flexibility of our model to navigate a highly dynamic environment,...

Interim data from Part A of the RINGSIDE study demonstrated substantial initial anti-tumor activity for AL102 as a single agent and supports continued development More advanced and comprehensive data set from RINGSIDE to be presented at ESMO REHOVOT, Israel and WILMINGTON, Del., Aug. 15, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced second-quarter 2022 financial results and provided a corporate update. “We continue to make considerable progress across our pipeline, and we were particularly excited to announce interim results from the ongoing Phase 2/3 RINGSIDE trial evaluating AL102...

NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) — TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or “the Company”), an explorer of lower-impact battery metals from seafloor polymetallic nodules, today provided a corporate update and financial results for the second quarter ending June 30, 2022. Financial HighlightsNet loss of $12.4 million and loss per share of $0.05 for the quarter ended June 30, 2022. Total cash on hand of approximately $46.3 million at June 30, 2022. The Company announced today a private placement financing for an aggregate of 38 million common shares to investors at a price per share of $0.80 ($0.9645 for TMC Chairman & CEO Gerard Barron), with expected gross proceeds of $30.4 million. Approximately 70% of the commitments came from existing TMC shareholders and insiders, including Allseas, ERAS Capital (the...

Successfully completed PM-602 human study for its targeted therapeutics platform demonstrating promising device performance in active ulcerative colitis patients Successfully completed PM-611 human study for its targeted therapeutics platform in healthy volunteers showing promising performance regardless of feeding schedule Confirmed planned phase 1 IND filing in Q1 based on FDA feedback on PGN-600 program in ulcerative colitis Strengthened patent position for both targeted and systemic therapeutics platforms Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today provided a corporate update and reported financial results for the second quarter ended...

– Lead development candidate selected from SENTI-202 program; on track for IND filing in 2023 – – Expect to present CAR-NK cell therapy program data at multiple scientific conferences in 2022 – – Cash position of $139.8 million as of June 30, 2022 expected to fund current operating plan into 2024 – SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today reported financial results for the second quarter ended June 30, 2022, and highlighted recent corporate accomplishments, including the selection of a lead development candidate from its SENTI-202 program with an anticipated Investigational New Drug (IND) application...